13
Participants
Start Date
May 25, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Pegvaliase-Pqpz
Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]
University of Missouri, Columbia
Boston Children's Hospital, Boston
Collaborators (1)
BioMarin Pharmaceutical
INDUSTRY
University of Missouri-Columbia
OTHER